Johns Hopkins University

Wake Forest University

University of Michigan

Canji Inc.

Stichting Katholieke Universiteit, the University Medical Centre Nijmegen

Stichting Katholieke Universiteit, More Particularly the University Medical Centre Nijmegen

Stichting Katholieke Universiteit More Particularly the University Medical Centre

Stichting Katholieke Universiteit, More Particularly the University of Medical Centre Nijmegen

William B Isaacs

Jun Luo

Marion J G Bussemakers

Jianfeng Xu

George Steven Bova

Thomas Dunn

Rong Hu

William G Nelson

Patrick C Walsh

Deborah Meyers

Eugene Roland Bleecker

Sigun Zheng

David Herrington

Christian P Pavlovich

Jillian N Eskra

Srinivasan Yegnasubramanian

G Steven Bova

Henrik Grönberg

Changxue Lu

Emmanuel S Antonarakis

Robert Bookstein

Wen-Hsiang Lee

Martin Aryee

Kathleen A Cooney

Marion Bussemakers

Disclosed herein are methods for a RNA in situ hybridization assay workflow for the detection of target RNA within intact cells for the detection of prostate cancer cells in urine samples. The methods disclosed herein can identify a genetic susceptibility to prostate cancer in a subject and differentiate high risk from low risk prostate cancers. The methods disclosed herein can also include treatment and management strategies for prostate cancer and the prevention thereof.

Methods for prostate cancer detection

The invention features diagnostic and therapeutic methods and compositions featuring androgen receptor variant proteins and nucleic acid molecules whose expression is increased in androgen related diseases or disorders.

Compositions and methods for treating or preventing prostate cancer and for detecting androgen receptor variants

Disclosed herein are compositions and methods for detecting biological molecules and biomarkers associated with prostate cancer. Disclosed herein are compositions and methods for detecting biological molecules and biomarkers associated with castration-resistant prostate cancer wherein such biological molecules and biomarkers comprise androgen-receptor splice variants that can be used to develop effective therapeutic regimens for prostate cancer patients. Disclosed herein are methods of using biological molecules and biomarkers related to androgen-receptor splice variants for assessing therapeutic resistance to drugs such as enzalutamide and abiraterone.

Methods and compositions related to prostate cancer therapeutics

The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions useful for assessing prostate cancer. In a specific embodiment, present inventors have developed and applied a new technology and associated computation methods enabling simultaneous genome-scale analysis of genetic (copy number) and epigenetic (total methylation (TM) and allele-specific methylation (ASM) alternation, This method, called MBD-SNP, features affinity enrichment or methylated genomic DNA fragments using a methyl-binding domain polypeptide.

DNA methylation markers for metastatic prostate cancer

Compositions and methods for the diagnosis, treatment and prevention of prostate cancer, well as for treatment selection.

Compositions and methods for the treatment of prostate carcinoma

The present invention relates, in general, to a prostate-specific antigen, PCA3. In particular, the present invention relates to nucleic acid molecules coding for the PCA3 protein; purified PCA3 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to PCA3 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding PCA3 proteins; a method of detecting nucleic acids encoding PCA3 proteins or polypeptides in a sample; kits containing nucleic acid probes or antibodies; bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with prostate cancer; therapeutic uses; and methods of preventing prostate cancer in an animal.

PCA3 genes

The present invention provides a method of identifying a subject as having an increased risk of having or developing aggressive prostate cancer, comprising detecting in the subject the presence of various polymorphisms associated with an increased risk of having or developing aggressive prostate cancer.

Methods and compositions for correlating genetic markers with risk of aggressive prostate cancer

PCA3, PCA3 genes, and methods of use

The present invention discloses methods of screening a subject for increased likelihood or risk of certain diseases or disorders. This method comprises detecting the presence or absence of at least one mutation in the MSR1 gene wherein the presence or absence of such mutation indicates an increased risk for certain diseases, such as cancer asthma and/or cardiovascular diseases.

Mutations in the macrophage scavenger receptor 1 gene alter risk of prostate cancer, asthma, and cardiovascular disease

The present invention relates, in general, to a prostate-specific antigen, PCA3. In particular, the present invention relates to nucleic acid molecules coding for the PCA3 protein; purified PCA3 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to PCA3 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding PCA3 proteins; a method of detecting nucleic acids encoding PCA3 proteins or polypeptides in a sample; kits containing nucleic acid probes or antibodies; bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognose a mammal afflicted with prostate cancer; therapeutic uses; and methods of preventing prostate cancer in an animal.

Growing community of inventors

Glyndon, MD, United States of America

William B Isaacs